Free Access
Issue
Med Sci (Paris)
Volume 26, Number 12, Décembre 2010
Page(s) 1087 - 1094
Section Repères
DOI https://doi.org/10.1051/medsci/201026121087
Published online 15 December 2010
  1. Plotkin SL, Plotkin SA. A short story of vaccination. In : Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia : WB Saunders, 2004 : 1-15. [Google Scholar]
  2. INPES. Baromètre santé 2005. http://www.inpes.sante.fr/index2. asp?page=Barometres/Baro2005_1R/synthese/vaccination.asp [Google Scholar]
  3. Jestin C. INPES. Communication personnelle. [Google Scholar]
  4. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch Dis Child 2002 ; 87 : 22-5. [Google Scholar]
  5. Wolfe RM, Sharp LK, Lipsky MS. Content and design attributes of antivaccination web sites.JAMA 2002 ; 287 : 3245-8. [Google Scholar]
  6. Jestin C, Gautier A. Perception de la vaccination par les médecins généralistes. Actualité et Dossier en Santé Publique 2010 ; 71 : 31-4. [Google Scholar]
  7. Voltaire. Lettre XI : sur l’insertion de la petite vérole. In : Lettres philosophiques. 1734. http://www.voltaire-integral.com/Html/22/11_Lettre_11.html [Google Scholar]
  8. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004 ; 82 : 16-23. [Google Scholar]
  9. Messiah A, Flahaut A. Absence de liaison entre la vaccination tétravalente et le syndrome de mort subite du nourrisson (enquête cas-témoins DGS/Inserm 1986). BEH 1986 ; 52 : 205-6. [Google Scholar]
  10. Miller DL, Ross EM, Alderslade R, et al. Pertussis immunisation and serious acute neurological illness in children. Br Med J 1981 ; 282 : 1595-9. [Google Scholar]
  11. Shields WD, Nielsen C, Buch D, et al. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 1988 ; 113 : 801-5. [Google Scholar]
  12. Wakefield AJ, Murch SH, Anthony A, et al. Ileal lymphpoid nodular hyperplasia, non specific colitis, and pervasive developmental disorders in children. Lancet 1998 ; 351 : 637-41. [Google Scholar]
  13. Wakefield AJ. Enterocolitis, autism and measles virus. Mol Psychiatry 2002 ; 7 (suppl 2) : S44-6. [Google Scholar]
  14. Gherardi RK, Coquet M, Chérin P, et al. Macrophagic myofasciitis: an emerging entity. Groupe d’étude et de recherche sur les maladies musculaires acquises et dysimmunitaires (GERMMAD) de l’Association française contre les myopathies (AFM). Lancet 1998 ; 352 : 347-52. [Google Scholar]
  15. Siegrist CA. Les adjuvants vaccinaux et la myofasciite à macrophages. Arch Pediatr 2005 ; 12 : 96-101. [Google Scholar]
  16. Mikaeloff Y, Caridade G, Assi S, et al. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demeylination. Brain 2007 ; 130 : 1105-10. [Google Scholar]
  17. Mikaeloff Y, Caridade G, Rossier M, et al. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007 ; 161 : 1176-82. [Google Scholar]
  18. Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009 ; 72 : 1260-6. [Google Scholar]
  19. Offit PA. Thimerosal and vaccines: a cautionary tale. N Engl J Med 2007 ; 357 : 1278-9. [Google Scholar]
  20. Floret D. Faut-il abroger les obligations vaccinales ? Arch Pediatr 2006 ; 13 : 423-5. [Google Scholar]
  21. Schwarzinger M, Flicoteaux R, Cortarenoda S, et al. Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance? PloS One 2010 ; 5 : e10199. [Google Scholar]
  22. SteelFisher GK, Blendon RJ, Bekheit MM, Lubell K. The public’s response to the 2009 H1N1 influenza pandemic. N Engl J Med 2010 ; 362 : e65. [Google Scholar]
  23. European Commission. Influenza H1N1. Analytical report. Publication : mars 2010. http:// ec.europa.eu/public_opinion/flash/fl_287_en.pdf. [Google Scholar]
  24. Hernan MA, Jick SS, Olik MJ, Kick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004 ; 63 : 638-42. [Google Scholar]
  25. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004 ; 363 : 750. [Google Scholar]
  26. Horton R. A statement by the editors of the Lancet. Lancet 2004 ; 363 : 820-1. [Google Scholar]
  27. Lyall J. Editor in the eye of the storm. Br Med J 2004 ; 328 : 528-8. [Google Scholar]
  28. The Editors of The Lancet. Retraction. Ileal-lymphoid hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. Lancet 2010 ; 375 : 445. [Google Scholar]
  29. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004 ; 114 : 793-804. [Google Scholar]
  30. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neurospychological outcomes at 7 and 10 years. N Engl J Med 2007 ; 357 : 1281-92. [Google Scholar]
  31. Kimura M. Japanese experience with acellular pertussis vaccines. Dev Biol Stand 1991 ; 73 : 5-9. [Google Scholar]
  32. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996 ; 18 : 99-117. [Google Scholar]
  33. Siegrist CA, Lewis EM, Eskola J, et al. Human papilloma virus immunization in adolescent and young adults. A cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007 ; 26 : 979-84. [Google Scholar]
  34. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic HINI influenza vaccines. Lancet 2009 ; 374 : 2115-22. [Google Scholar]
  35. Coignard-Biehler H, Lortholary O. Cabale contre la vaccination anti-H1N1 : est-elle justifiée ? Med Sci (Paris) 2009 ; 25 : 967-70. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.